Zimmer Biomet Holdings Inc
$ 96.52
1.24%
14 Apr - close price
- Market Cap 18,653,460,000 USD
- Current Price $ 96.52
- High / Low $ 97.81 / 95.09
- Stock P/E 26.86
- Book Value 64.95
- EPS 3.55
- Next Earning Report 2026-04-28
- Dividend Per Share $0.96
- Dividend Yield 1.03 %
- Next Dividend Date 2026-04-30
- ROA 0.04 %
- ROE 0.06 %
- 52 Week High 107.45
- 52 Week Low 84.36
About
Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.
Analyst Target Price
$102.95
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-10-30 | 2025-08-07 | 2025-05-05 | 2025-02-06 | 2024-10-30 | 2024-08-07 | 2024-05-02 | 2024-02-08 | 2023-11-07 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 2.42 | 1.9 | 2.07 | 1.81 | 2.31 | 1.74 | 2.01 | 1.94 | 2.2 | 1.65 | 1.82 | 1.89 |
| Estimated EPS | 2.3978 | 1.88 | 1.98 | 1.77 | 2.29 | 1.74 | 1.99 | 1.87 | 2.15 | 1.6 | 1.81 | 1.64 |
| Surprise | 0.0222 | 0.02 | 0.09 | 0.04 | 0.02 | 0 | 0.02 | 0.07 | 0.05 | 0.05 | 0.01 | 0.25 |
| Surprise Percentage | 0.9258% | 1.0638% | 4.5455% | 2.2599% | 0.8734% | 0% | 1.005% | 3.7433% | 2.3256% | 3.125% | 0.5525% | 15.2439% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-28 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.86 |
| Currency | USD |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-30 | 2026-01-30 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 |
| Amount | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 | $0.24 |
Next Dividend Records
| Dividend per share (year): | $0.96 |
| Dividend Yield | 1.03% |
| Next Dividend Date | 2026-04-30 |
| Ex-Dividend Date | 2026-03-31 |
Recent News: ZBH
2026-04-14 19:12:33
A shareholder proposal at Zimmer Biomet Holdings (NYSE:ZBH) calls for separating the roles of Board Chairman and CEO, a move the current board advises against. This vote highlights governance and accountability concerns amidst mixed stock performance, with the stock seeing a 4.8% gain over the past week and 5.9% year to date, but a 40.6% decline over five years. The outcome of the vote could significantly influence investor perception of the company's oversight, risk management, and succession planning.
2026-04-14 19:10:15
Smith & Nephew plc, a global medical technology company listed in London, offers U.S. investors exposure to the resilient orthopaedics market, driven by aging populations and demand for joint replacements. The company diversifies its revenue across orthopaedics, sports medicine, and advanced wound management, maintaining a strong competitive edge through innovation and surgeon preference. Key risks include supply chain disruptions, regulatory hurdles, and currency volatility, but analysts generally view the company positively for its defensive growth and innovation pipeline.
2026-04-14 14:09:08
Zimmer Biomet, a leader in orthopedic devices, maintains a strong position in the knee and hip implant market, driven by an aging global population and consistent demand for joint replacements. The company leverages innovation with products like the Persona Knee and ROSA Robotics platform, alongside strategic acquisitions, to ensure stable revenue streams in the resilient healthcare sector. Despite competitive pressures and supply chain challenges, analysts view Zimmer Biomet cautiously optimistic due to its consistent growth, strong market presence, and focus on high-demand segments.
2026-04-14 13:54:57
Zimmer Biomet (US98956P1021) is a leading orthopedic device company, dominant in knee and hip replacements, with a strong focus on innovation and strategic acquisitions. The article highlights the company's resilient business model driven by aging populations and elective surgeries, particularly in the US and other English-speaking markets. Despite competitive pressures and supply chain risks, analysts are cautiously optimistic about its long-term growth due to its strong product portfolio, including the Persona Knee and ROSA Robotics, and stable healthcare spending.
2026-04-14 11:10:15
Smith & Nephew plc is well-positioned for growth in the global medtech sector, particularly in orthopedics and sports medicine, driven by an aging population and increasing demand for joint replacements. The company's diversified business model, focus on innovation, and strong market presence in the U.S. and other English-speaking markets make it an attractive option for investors seeking exposure to resilient healthcare spending. Key growth drivers include accelerated innovation in robotics and digital surgery, expanding market access, and operational discipline, despite facing risks such as supply chain disruptions and competitive pressures.
2026-04-13 21:08:43
Zimmer Biomet Holdings, a leader in musculoskeletal healthcare, faces increasing scrutiny regarding supply chain resilience amidst a push for stronger industrial supply chains in the U.S. The company's ability to navigate these pressures and technological shifts will be crucial for its future growth, despite strong demand driven by aging populations and orthopedic procedure growth. Analysts maintain a cautiously optimistic view, with the company's strong balance sheet and leadership in areas like robotics positioning it for long-term gains, while highlighting risks such as supply chain disruptions and competitive dynamics.
